



VALUABLE STRATEGIES TO REDUCE THE RISK FOR AND CLINICAL IMPACT OF HYPERKALEMIA

Reference List

1. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. *Arch Intern Med.* 1998;158:917-924.
2. AstraZeneca. AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalaemia. <https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-receives-complete-response-letter-from-us-fda-for-sodium-zirconium-cyclosilicate-zs-9-for-oral-suspension-for-treatment-of-hyperkalaemia-27052016.html>. Published May 27, 2016. Accessed August 31, 2016.
3. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN randomized clinical trial. *JAMA.* 2015;314:151-161.
4. Ballantyne F III, Davis LD, Reynolds EW Jr. Cellular basis for reversal of hyperkalemic electrocardiographic changes by sodium. *Am J Physiol.* 1975;229:935-940.
5. Batterink J, Lin J, Au-Yeung SH, Cessford T. Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia. *Can J Hosp Pharm.* 2015;68(4):296-303.
6. Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. *Curr Med Res Opin.* 2018 Feb 21:1-8. doi: 10.1080/03007995.2018.1433141.
7. Blumberg A, Weidmann P, Shaw S, Gnädinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. *Am J Med.* 1988 Oct;85(4):507-12.
8. Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. *Kidney Int.* 2015;88(6):1427-1433.
9. Buysse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. *Future Cardiol.* 2012;8:17-28.
10. Chen W, Abramowitz MK. Metabolic acidosis and the progression of chronic kidney disease. *BMC Nephrol.* 2014;15:55.
11. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med.* 2009;169:1156-1162.
12. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care.* 2015 Sep;21(11 Suppl):S212-20.
13. Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on Medicare and commercial payers. *Am Health Drug Benefits.* 2017 Jun;10(4):202-210.



VALUABLE STRATEGIES TO REDUCE THE RISK FOR AND CLINICAL IMPACT OF HYPERKALEMIA

14. Floege J, Johnson RJ, Feehally J, eds. *Comprehensive Clinical Nephrology*. 4th ed. St. Louis: Mosby; 2010.
15. Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. *J Am Soc Nephrol*. 1998;9:1924-1930.
16. Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. *Clin Nephrol*. 2016;85(1):38-43.
17. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. *Nephron Clin Pract*. 2012;120:c8-16.
18. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. *Am J Med*. 2013;126(3):264-24.
19. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med*. 2004;351:543-551.
20. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? *Nephrol Dial Transplant*. 2012;27:4294-4297.
21. Kayexalate [package insert]. Cary, NC: Covis Pharmaceuticals, Inc.; 2013.
22. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. International Society of Nephrology. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO_BP_GL.pdf. Published 2012. Accessed April 14, 2016.
23. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. *JAMA*. 2014;312:2223-2233.
24. Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. *Clin J Am Soc Nephrol*. 2015;10:2136-2142.
25. Lopes RJ, Lourenco AP, Mascarenhas J, Azevedo A, Bettencourt P. Safety of spironolactone use in ambulatory heart failure patients. *Clin Cardiol*. 2008;31:509-513.
26. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371:993-1004.
27. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. *J Am Soc Nephrol*. 2009;20:2641-2650.
28. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. *Clin J Am Soc Nephrol*. 2008;3:324-330.
29. Mulkerrin E, Epstein FH, Clark BA. Aldosterone responses to hyperkalemia in healthy elderly humans. *J Am Soc Nephrol*. 1995;6:1459-1462.



VALUABLE STRATEGIES TO REDUCE THE RISK FOR AND CLINICAL IMPACT OF HYPERKALEMIA

30. National Kidney Foundation. Best practices in managing hyperkalemia in chronic kidney disease. Published 2016. Available at: <https://www.kidney.org/sites/default/files/02-10-7259%20Hyperkalemia%20Tool.pdf>. Accessed April 24, 2018.
31. National Kidney Foundation. Clinical update on hyperkalemia. Published 2014. Available at: https://www.kidney.org/sites/default/files/02-10-785_HBE_Hyperkalemia_Bulletin.pdf. Accessed April 24, 2018.
32. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. *N Engl J Med*. 2015;372:222-231.
33. Palmer BF, Sterns RH. Fluid, electrolyte, and acid-base disturbances. *NephSAP*. 2009;8(2).
34. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med*. 2004;351:585-592.
35. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012;367:2204-2213.
36. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. *Diabetes Care*. 2010;33:2304-2309.
37. Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. *Eur J Heart Fail*. 2015;17(10):1057-1065.
38. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999;341:709-717.
39. Polson M, Lord TC, Kangethe A, Speicher L, Farnum C, Brenner M, Oestreicher N, Alvarez P. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. *J Manag Care Spec Pharm*. 2017 Apr;23(4-a Suppl):S2-S9.
40. Rafique Z, Weir MR, Onuigbo M, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock WF. Expert panel recommendations for the identification and management of hyperkalemia and role of patiromer in patients with chronic kidney disease and heart failure. *J Manag Care Spec Pharm*. 2017 Apr;23(4-a Suppl):S10-S19.
41. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. *Clin J Am Soc Nephrol*. 2012;7:1234-1241.
42. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? *J Am Soc Nephrol*. 2010;21:733-735.
43. Sterns RH, Palmer BF. Fluid, electrolyte, and acid-base disturbances. *NephSAP*. 2007;6(4).
44. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, de Lima J. Effect on aging on plasma renin and aldosterone in normal man. *Kidney Int*. 1975;8:325-333.
45. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med*. 2015;372:211-221.
46. Weisberg LS. Management of severe hyperkalemia. *Crit Care Med*. 2008;36:3246-3251.



VALUABLE STRATEGIES TO REDUCE THE RISK FOR AND CLINICAL IMPACT OF HYPERKALEMIA

47. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239.
48. Yildirim T, Arici M, Piskinpasa S, et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? *Ren Fail*. 2012;34:1095-1099.
49. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358:1547-1559.
50. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*. 2011;364:11-21.

